Novogene(SH:688315) Zhong Guo Jing Ji Wang·2025-07-17 07:31Core Viewpoint - The company, 诺禾致源, has completed a share reduction plan by its shareholders, resulting in a total reduction of 8,077,677 shares, which is 2.94% of its total share capital [1][2]. Share Reduction Details - The shareholders, 致源禾谷 and 诺禾禾谷, reduced their holdings through centralized bidding and block trading, with a total of 2,898,677 shares (0.70%) and 5,179,000 shares (1.24%) sold respectively [1]. - The reduction occurred between April 16, 2025, and July 15, 2025, at prices ranging from 12.83 yuan to 14.99 yuan per share, totaling approximately 110.26 million yuan [1]. Shareholder Background - Prior to the reduction, 致源禾谷 held 47,106,622 shares (11.32%) and 诺禾禾谷 held 12,564,672 shares (3.02%) of 诺禾致源 [2]. - The controlling shareholder, 李瑞强, is a general partner of both 致源禾谷 and 诺禾禾谷, indicating they are acting in concert [2]. Initial Public Offering (IPO) and Fundraising - 诺禾致源 raised a total of 51.30 million yuan from its IPO, with a net amount of 44.98 million yuan after deducting issuance costs [3]. - The company planned to use the funds for projects related to gene sequencing service platform expansion, gene testing reagent development, and information technology infrastructure [3]. - In 2023, the company conducted a private placement, raising 332.16 million yuan, with a net amount of 327.61 million yuan after expenses [4]. - The total fundraising from the IPO and the 2023 private placement amounts to 84.51 million yuan [5].